CW February 2005
Volume 14Issue Number 2 February 2005 ISSN 10593802 New Advanced Prostate Cancer Agent Reduces and Delays Bone PainAmong men with metastatic hormone- refractory prostate cancer (HRPC), atrasentan (Xinlay™, Abbott) reduces the incidence of bone pain and delays its onset, according to a pooled meta-analysis presented at the Chemotherapy Foundation Symposium XXII in New York City.
Go to Previous Page Go to Next Page Source & Additional Reading M. Carducci, Chemotherapy Foundation Symposium XXII in New York City. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW February 2005Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
